Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer

Clinical Trial ID NCT00338884

Rank	Title	Journal	Year	PubWeight™‹?›
1	Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.	Proc Natl Acad Sci U S A	2007	4.08
2	Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.	Cancer	2011	2.38
3	Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.	Br J Cancer	2014	2.26
4	Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.	Eur Urol	2014	2.23
5	Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.	Clin Cancer Res	2015	1.53
6	Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.	Br J Cancer	2013	1.24
7	A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.	Curr Cancer Drug Targets	2012	1.12
8	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.	Eur Urol	2015	0.92
9	Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma.	Eur Urol	2015	0.84
10	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.	J Clin Oncol	2016	0.76
11	Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.	Eur Urol	2016	0.75